Michael J, Rosenberg, Dead Doctors and Obamacare 2
Records link a doctor killed in a Gaithersburg plane crash to a 2010 crash in an approach to the same Montgomery County Airpark.
Gaithersburg (WUSA9) – A doctor killed in Monday’s Gaithersburg, Md. small jet crash is linked to a 2010 crash which was also heading to the Montgomery County Airpark.
The 66-year-old North Carolina doctor and businessman is identified in records as owning both crashed airplanes and may have been the pilot of at least one.
Authorities are investigating to determine who was at the controls in Monday’s crash.
FAA records don’t identify the pilot in the 2010 crash, but according to a 2010 Gazette article, the pilot of that crash was the doctor, Michael Rosenberg.
The 66 year old Rosenberg was the founder of a Durham North Carolina based pharmaceutical research company, which issued a statement Monday saying he was killed in the recent small jet crash.
“Everyone at Health Decisions is devastated,” said the company statement. “The thoughts of the management and employees of Health Decisions go out to Dr. Rosenberg’s family.”
Health Decisions Statement December 8
Records show the plane in the 2010 crash and the jet in Monday’s crash are both registered to Rosenberg.
WUSA9 footage from Montgomery County Airpark in March of 2010 shows about a hundred foot long line in the mud leading from the runway to the brush and trees where the pilot got out uninjured.
According to a FAA report on the 2010 crash, just before impact a stall alarm sounded on Rosenberg’s eight passenger turbo prop, a Socata TBM-700.
The pilot attempted to abort the landing and make another attempt the plane drifted, climbing about ten feet, then crashed nose down.
The FAA blamed the 2010 accident on the pilot failing to maintain aircraft control.
Wednesday, March 3, 2010
Injury averted in plane crash at Montgomery County Airpark
Pilot was trying to land turbo-prop Monday night
by Sebastian Montes | Staff Writer
A single-engine plane crashed Monday evening as it tried to land at the Montgomery County Airpark, careening into a nearby stand of trees and leaving the pilot with non-life-threatening injuries.
Firefighters responding to a call from the airport near Montgomery Village shortly after 5:30 p.m. Monday found the plane in the woods next the 4,200-foot runway, said Capt. Oscar Garcia, spokesman for Montgomery County Fire and Rescue Services. There was no evidence of fire or smoke, Garcia said.
The plane is a Socata TBM 700, a turbo-propeller plane that seats up to eight people. It is registered to Michael J. Rosenberg and Nova Aviation LLC, based in Port Orange, Fla., according to FAA records.
Rosenberg was flying in on a business trip from North Carolina, said Keith Miller, executive director of the Montgomery County Revenue Authority, which owns and operates the 50-year-old airport.
“The pilot is OK. He didn’t even go to the hospital,” Miller said Monday night.
The runway closed for more than an hour after the crash. Federal and county officials did not immediately know the cause.
“It looks like it came up just short of [the] runway,” Jim Peters, a spokesman for the Federal Aviation Administration, said Monday night.
FAA investigators arrived at the crash scene Tuesday morning.
The National Transportation Safety Board links 83 accidents to the airpark since 1964, the most recent in March 2009, when the pilot of a Cirrus SR22 became disoriented after take-off, deployed the plane’s parachute and narrowly missed dozens of homes as it came down on a street in the Flower Hill community.
HEALTH DECISIONS CRO
Dr. Michael Rosenberg has been active in clinical research for more than 30 years, designing or conducting more than 300 studies worldwide in a range of therapeutic areas. Early in his career, he realized that excellence in clinical research requires elevating managerial standards to the same high level as scientific standards. He founded Health Decisions (www.HealthDec.com) in 1989 to develop a more efficient approach to managing clinical trials.
Under his guidance, Health Decisions has been recognized with many high-profile awards, including CIO’s Enterprise Value Award and the inclusion in Inc 500 and Technology Fast 500 fastest-growing private and technology-based companies, respectively. Ernst & Young also selected Dr. Rosenberg as Entrepreneur of the Year in Health Sciences.
Before founding Health Decisions, Dr. Rosenberg served as Executive Director and Chief Executive Officer of the American Social Health Organization, Director of the Reproductive Epidemiology Division of Family Health International, and Chief, Reproductive Health Activity, at Centers for Disease Control. He currently serves on the Leadership Council of the Harvard School of Public Health and as co-principal investigator of the Clinical and Statistical Coordinating Center for Contraceptive Research, National Institutes of Health. He has published more than 200 scientific articles, serves on the editorial boards of Current Drug Discovery and Contraceptive Technology Update, and is a reviewer for several journals.
Dr. Rosenberg also serves as Clinical Professor of Obstetrics and Gynecology at the University of North Carolina School of Medicine and Adjunct Professor of Epidemiology at the UNC School of Public Health. He is a Fellow of the American College of Physicians (Internal Medicine), the American College of Epidemiology, and the American College of Preventive Medicine. He completed his undergraduate and medical degrees at the University of California and received a Master’s Degree in Epidemiology and Biostatistics from the Harvard School of Public Health.
June 26, 2014
Durham, North Carolina. Health Decisions, the full-service CRO of choice for forward-looking biopharma and medical device companies, today announced database lock for Evofem’s phase 3 study of Amphora® nonhormonal contraceptive gel, the largest trial ever conducted of a nonhormonal contraceptive. Database lock marks an important milestone toward regulatory approval for Amphora, a potential alternative to Conceptrol®, the brand name of nonoxynol-9, the only spermicidal gel currently approved by the FDA.
“We are pleased to announce early database lock for this 3,389-subject global study of a potentially important new contraceptive alternative for women worldwide,” said Health Decisions CEO Michael Rosenberg, MD, MPH. “A combination of intensive study management based on streaming information and progressive subject-by-subject closeout enabled this important early step toward regulatory approval for a nonhormonal alternative to existing contraceptives.”
“We are excited to have reached this important milestone in the development of Amphora,” said Saundra Pelletier, CEO of Evofem Inc. “We really believe Amphora has tremendous potential to impact the lives of women, globally.”
Importance of Amphora’s Potential HIV-Preventative Effects If Confirmed
“We are excited about this Evofem development program both for now and future,” Rosenberg stated. “In the near term, Amphora, if approved as a contraceptive, will provide women around the world with greater contraceptive choice. It will have an important place as an inexpensive, easy-to-use, woman-controlled product used only when necessary and on demand.”
Looking at the longer term, Rosenberg said, “Although research will have to confirm this, Amphora may ultimately provide women for the first time with a single product that offers a combination of broadly effective contraception and HIV preventative effects.” Rosenberg stated that this unique combination could have important implications for global world health, in part because, according to the World Health Organization and FDA-mandated labeling requirements in effect since December 2007, the currently marketed nonoxynol-9 vaginal gel may actually increase the risk of acquisition of HIV in some circumstances.
Largest Contraceptive Trial of Its Type Enrolled 3x-4x Faster
Rosenberg, recently honored by the Association of Clinical Research Professionals with its 2014 Award for Innovation in Clinical Research, stated that Health Decisions’ innovative technology and processes enabled highly efficient study execution from startup through the most recent milestone, database lock.
“Our agile enrollment techniques enabled us to enroll almost 3,400 subjects three to four times faster than previous trials of similar products that enrolled less than half as many subjects. We enrolled 125 subjects per month compared with 38 subjects per month and 30 subjects per month for previous large studies of similar products. Our Agile Risk-Based Monitoring+ approach also enabled us to increase data quality simultaneously with reducing the percentage of data that was source verified.”
About Health Decisions
Health Decisions is the CRO of choice for forward-looking biopharma and medical device companies and a driving force in the modernization of clinical development. Health Decisions uses data-driven insight and agility to deliver clinical development success, reduce timelines and risk and increase quality and returns for biopharma and medical device companies worldwide. For 25 years and in more than 300 clinical trials involving tens of thousands of patients in many therapeutic areas, Health Decisions has improved the efficiency of clinical development through innovative methodology, processes and technology. Health Decisions’ clinical-development services have enabled biopharma and device companies to bring new products to market faster and at lower cost, thus providing the public with earlier access to improved treatments and diagnostics at more affordable prices. Health Decisions is headquartered in Durham, NC and operates on five continents.
Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with WomanCare Global, a nonprofit organization whose mission is to provide access to quality, affordable, women’s healthcare products through a sustainable supply chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, WomanCare Global provides sales, marketing and global distribution support to Evofem’s products.
Experience in Vaccine Clinical Trials
Health Decisions has conducted clinical trials of prophylactic and therapeutic vaccines for a variety of indications, including influenza, cytomegalovirus, and renal cell carcinoma. The methods that Health Decisions has developed for such studies are ideal for early phase studies of many types of prophylactic vaccines, including:
- Hepatitis A, B and C
- Herpes Zoster
- Influenza, including TIV, H1N1
- Meningococcal Meningitis
February 4, 2010 – Health Decisions, a full-service clinical research organization (CRO) specializing in high-efficiency adaptive solutions, has completed enrollment for a phase II universal flu vaccine study three weeks after the first site initiation visit and less than three months after the partnership was contracted…..
The vaccine’s developers chose to partner with Health Decisions for the CRO’s ability to meet two critical requirements that were vital to the study’s early success. First, all subjects had to be administered doses before the standard flu vaccine, to which the candidate was being compared, reached its expiration date. Missing this deadline would have meant losing months of progress waiting for a new batch to become available. In addition, reactogenicity data had to be captured, verified and made accessible to the sponsor immediately in order to closely monitor patients’ tolerability levels.
“The sponsor’s tight schedule and safety monitoring requirements presented a great opportunity for us to prove the capabilities of our Agile Clinical Development platform. We’re proud to support such an important medical breakthrough, and look forward to a bright future working with the sponsor to make vaccines more accessible to patients.”
Associate Director of Clinical Affairs
Who or WHO is the partner, developer and sponsors
Contracts to Contractor(s) “HEALTH DECISIONS INC.”
(FY 2000-2012) FedSpending.org
# # # other # # #
Latin, modification of Greek amphoreus, amphiphoreus, fromamphi- + phoreus bearer, from pherein to bear
Evofem has received significant private funding for the development of Amphora. In addition, public organizations and foundations invested substantial funds into the early development of the product, prior to its acquisition by Evofem. Early funders of the product included CONRAD, the Centers for Disease Control and Prevention, and the National Institute of Health, among others.
CONRAD Support Since 2008
USAID (Population and Contraception)
NIAID U19 Subawards and Other Microbicide Funding
Gates Foundation (Contraception)
Gates Foundation (Microbicides)
Other Private Foundation
1911 North Fort Myer Drive
Arlington, VA 22209
2013 Statement from the
Bellagio Group on LARCs
Evofem LLC is a privately held biotechnology company that brings advanced prescription and consumer products to global markets. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of dermatology, pain management, feminine care, contraception, and the prevention of sexually transmitted infections. In February 2013, Evofem entered into a strategic alliance with Woman Care Global, a nonprofit organization whose mission is to provide access to quality, affordable, women’s healthcare products through a sustainable value chain in over 100 countries, with a particular focus on under-served markets in Africa, Asia, and Latin America. Through this alliance, Woman Care Global provides sales, marketing and global distribution support to Evofem’s products.
# # # other # # #
# # # other # # #
Group of Thirty – Medicago DARPA – coto2
As I have discussed in several posts, the everything vaccine will dominate and control billions of dollars while providing the sterilization (advanced nano-tech versions) through assorted pharma and M2e peptide adjuvants and synthetic protein cellular killers. Here is a short list of the competitors, many at the Research Triangle
Acambis, VaxInnate, Merck, Vical and Dynavax Technologies Corporation, VaxInnate, Crucell NV, Inovio Pharmaceutical, Immune Targeting Systems, Israel’s BiondVax, Etubics Corp, FluGen, Gamma Vaccines and PT Bio Farma in Indonesia. The weather wars and Typhoons are involved in this as are Malaysia Flights MH17 and 370. There are no doubts this was a WELLSTONE hit assassination. Because the HEALTH DECISIONS and GOOGLEPLEX have not identified the Level PHASE II Vaccine sponsor and client, we can only guess what BIOTERRORIST group was involved or did it go higher to the Gang of 30, Gates and Rockefeller committee. Maybe someone will break further news. Below is a youtube by a gentlemen who also sees this was a hit or at least suspicious.
Tags: Fiscal eBola, Triangle Park, EMR, Bioterrorism, Agenda 21, Eugenics, Human Reproduction, Depopulation, Assassinations, Technocracy, Wellstoned, Dead Scientists, Covert Domestic Terrorism, NSA spying, Whistleblowers, Ft. Detrick, Research Triangle Park, USAMRIID, AIDS-HIV